How we can fight antibiotic-resistant superbugs with a new class of vaccines

The alarming rise of "superbugs" could claim up to 10 million lives globally by 2050 due to their unique ability to resist antibiotics.


About the talk

The alarming rise of "superbugs" could claim up to 10 million lives globally by 2050 due to their unique ability to resist antibiotics. However, pharmacist Vikas Jaitely is researching ways we can battle these drug-resistant bacteria — by studying how they evolve in order to create more effective treatments and vaccines.

About the speaker

Vikas Jaitely · Pharmaceutical engineer

Vikas Jaitely is a pharmacist with a PhD in pharmaceutics and drug delivery systems. He has more than 17 years of experience working in the pharmaceutical industry. Jaitely joined Merck KGaA, Darmstadt, Germany in 2017 from the UK Medicine and Healthcare products Regulatory Agency (MHRA), where he worked as a senior assessor and team manager. He was awarded the Maplethorpe Fellowship by University College London for his work on drug-delivery systems and has authored 23 original research papers in peer-reviewed journals.

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement